Unexplained Chronic Cough: Diagnosis and Treatment
This patient likely has unexplained chronic cough (UCC), and you should offer multimodality speech pathology therapy as first-line treatment, with gabapentin as a second-line option if speech therapy fails or is unavailable.
Diagnostic Approach
Before confirming UCC, you must complete a structured workup to exclude treatable causes 1:
Required Testing
- Objective testing for bronchial hyperresponsiveness (methacholine challenge) OR therapeutic corticosteroid trial
- Eosinophilic bronchitis testing: sputum eosinophils or exhaled nitric oxide
- Ensure previous imaging was adequate (chest x-ray at minimum)
Critical Exclusions
The diagnosis of UCC requires that cough persists >8 weeks and remains unexplained after:
- Systematic investigation completed
- Supervised therapeutic trials conducted according to best-practice guidelines
- Patient adherence to treatment trials confirmed 1
Common pitfall: Many patients are incorrectly labeled as having "unexplained cough" when the actual problem is inadequate investigation or suboptimal treatment trials 2. Before accepting this diagnosis, verify that empiric trials were truly adequate for:
- Upper airway cough syndrome (postnasal drip)
- Cough-variant asthma
- Gastroesophageal reflux disease (if symptoms present)
Treatment Algorithm
First-Line: Speech Pathology Therapy
Recommend multimodality speech pathology-based cough suppression therapy 1. This intervention has demonstrated improvement in cough severity and quality of life with minimal side effects.
Second-Line: Gabapentin
If speech therapy is unavailable or ineffective, offer gabapentin with careful counseling 1:
Dosing regimen:
- Start: 300 mg once daily
- Titrate: Add additional daily doses as tolerated
- Target: Up to 1,800 mg/day in two divided doses (maximum tolerable dose)
Critical counseling points:
- Discuss potential side effects and risk-benefit profile before starting
- Reassess risk-benefit at 6 months before continuing 1
- Gabapentin improves quality of life in randomized trials, which may outweigh side effects given the significant QOL impairment these patients experience
What NOT to Do
Avoid inhaled corticosteroids if testing for bronchial hyperresponsiveness and eosinophilia (sputum eosinophils, exhaled nitric oxide) is negative 1. Grade 2B recommendation against their use in this setting.
Avoid proton pump inhibitors if workup for acid gastroesophageal reflux disease is negative 1. Grade 2C recommendation against empiric PPI therapy without evidence of GERD.
Key Clinical Nuances
Quality of life impact: UCC causes significant impairment in health-related quality of life, often persisting for months to years 1. This justifies more aggressive treatment approaches including gabapentin despite potential side effects.
Prevalence: UCC occurs in 5-10% of patients seeking care for chronic cough and up to 46% of specialty cough clinic referrals 1, so this is not a rare diagnosis when properly evaluated.
Multiple causes: Remember that 20% of chronic cough patients have more than one contributing cause 3. If initial treatment fails, reconsider whether all potential causes were adequately addressed rather than immediately labeling as refractory.
Practical Implementation
For this 67-year-old woman:
- Confirm testing for bronchial hyperresponsiveness and eosinophilic bronchitis was completed (or perform therapeutic corticosteroid trial)
- If negative, refer to speech pathology for multimodality cough suppression therapy
- If speech therapy unavailable or fails after adequate trial, initiate gabapentin 300 mg daily with dose escalation protocol
- Schedule 6-month reassessment if using gabapentin
- Consider specialty cough clinic referral if both interventions fail 1